Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bifeprunox, olanzapine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Bifeprunox | DRUG | - |
| bifeprunox, olanzapine | DRUG | - |
Inclusion Criteria: 1. Outpatients who have successfully completed Wyeth study 3168A1-311-US. 2. A signed and dated informed consent form for this study. 3. No major protocol violations in previous study. Exclusion Criteria: 1. Clinically important abnormalities noted in preceding short-term stud...
Bifeprunox is an investigational small molecule being studied for psychiatric conditions, including bipolar depression, schizophrenia, and bipolar disorder. It has been evaluated in clinical trials for these indications, though it is not approved and remains in clinical development.
Bifeprunox is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug has been studied in Phase 3 clinical trials for psychiatric indications.
Bifeprunox has been studied in Phase 3 clinical trials for bipolar depression and schizophrenia, as well as in a Phase 1 trial in healthy subjects. It is an investigational drug and is not approved for any use.
Bifeprunox has been evaluated in several completed trials, including NCT00245973 for bipolar depression, NCT00366171 and NCT00380224 for schizophrenia, and NCT00581451 in healthy subjects. These trials were conducted in the United States and enrolled adults aged 18 years and older.
Bifeprunox is a distinct investigational compound developed by Pfizer. No alternative names for Bifeprunox have been reported in the clinical trial records.